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Abstract
Background: The composition of the skin microbiome is predicted to play a role in the development of conditions
such as atopic eczema and psoriasis. 16S rRNA gene sequencing allows the investigation of bacterial microbiota. A
significant challenge in this field is development of cost effective high throughput methodologies for the robust
interrogation of the skin microbiota, where biomass is low. Here we describe validation of methodologies for 16S rRNA
(ribosomal ribonucleic acid) gene sequencing from the skin microbiome, using the Illumina MiSeq platform, the
selection of primer to amplify regions for sequencing and we compare results with the current standard protocols..
Methods: DNA was obtained from two low density mock communities of 11 diverse bacterial strains (with and
without human DNA supplementation) and from swabs taken from the skin of healthy volunteers. This was amplified
using primer pairs covering hypervariable regions of the 16S rRNA gene: primers 63F and 519R (V1-V3); and 347F and
803R (V3-V4). The resultant libraries were indexed for the MiSeq and Roche454 and sequenced. Both data sets were
denoised, cleaned of chimeras and analysed using QIIME.
Results: There was no significant difference in the diversity indices at the phylum and the genus level observed
between the platforms. The capture of diversity using the low density mock community samples demonstrated
that the primer pair spanning the V3-V4 hypervariable region had better capture when compared to the primer
pair for the V1-V3 region and was robust to spiking with human DNA. The pilot data generated using the V3-V4
region from the skin of healthy volunteers was consistent with these results, even at the genus level (Staphylococcus,
Propionibacterium, Corynebacterium, Paracoccus, Micrococcus, Enhydrobacter and Deinococcus identified at similar
abundances on both platforms).
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Conclusions: The results suggest that the bacterial community diversity captured using the V3-V4 16S rRNA
hypervariable region from sequencing using the MiSeq platform is comparable to the Roche454 GS Junior
platform. These findings provide evidence that the optimised method can be used in human clinical samples
of low bacterial biomass such as the investigation of the skin microbiota.
Keywords: Skin microbiome, Bacterial microbiome, Low biomass, 16s rRNA gene, Miseq platform, Next
generation sequencing, Methods, Optimisation, Primer selection
Background
The existence of commensals is well established, with
the term ‘human microbiome’ being used to describe the
sum of all the micro-organisms including bacteria, fungi,
viruses, archae and eukaryotes that live in or on a hu-
man host at a given time [1]. In recent years, as a result
of initiatives such as the NIH Human microbiome pro-
ject, the scientific community has made great progress
in cataloguing these micro-organisms [2–5]. One of the
most common sites for investigation is skin, due to the
ease of sampling and the potential role of the skin
microbiome in the aetiology of skin diseases, such as
atopic eczema and psoriasis [6–9]. A challenge in study-
ing the skin microbiome is that healthy skin generally
harbours a low microbial biomass; several amplification
steps are, therefore, required before sufficient starting
material is available for the commonly used DNA
sequencing approaches and this increases the risk of
introducing sequence artifacts (e.g. chimeric DNA frag-
ments) or detecting contamination from the environ-
ment or reagents used [10].
Early studies used amplification, sub-cloning and Sanger
sequencing of the highly conserved 16S rRNA gene, which
can provide sequence information over the entire length
of the 16S rRNA gene in a single reaction. Although this
is still the most comprehensive method of bacterial identi-
fication, it is expensive and time consuming. Next gener-
ation sequencing (NGS) technologies make it possible to
carry out identification of members of the microbial com-
munity at a much lower cost and with a higher with a
higher throughput. Although some regions in the 16S
rRNA gene sequence are highly conserved within bacterial
species, nine hypervariable regions can be used to deter-
mine the identity of different species or genera of bacteria;
amplification of short read lengths across these hypervari-
able regions are sufficient for taxonomic assignment of
bacteria [11] to the genus level. Hence, NGS platforms
provide an ideal technology for studies of the microbiome
despite the fact that the current NGS platforms are only
able to generate relatively short read lengths (modal read
lengths of 150 to 518 base pairs (bp)) [12, 13]. However, it
is important to select the most appropriate hypervariable
region for each sample type being analysed, as ‘primer
bias’ [14] (selective loss of bacterial groups due to the in-
ability to accurately sequence/identify certain bacteria),
may limit the diversity of the bacterial species that can be
identified in a sample. As bacterial diversity is variable
across different niches, careful selection of the primers for
16S amplicon generation is essential so that the particular
hypervariable region sequenced results in the most com-
prehensive capture of the microbial diversity for the niche
under investigation [15].
Until recently, much of the NGS work on the human
microbiome was performed using the Roche 454 NGS
platform, which offers up to 1000 bp reads. However, in-
creasingly, microbiome studies are utilising newer NGS
platforms, such as the Illumina MiSeq, which have been
reported to be more cost effective and accurate, but have
shorter read lengths [13, 16]. The V4 hypervariable re-
gion is traditionally selected for work on the MiSeq as it
provides adequate information for taxonomic classifica-
tion of microbial communities and has demonstrated a
lower error rate on the Illumina platform [17]. However,
to accommodate the current MiSeq protocol (250 bp
paired end sequencing), a longer region (~500 bp) of the
16S rRNA gene was considered for the current work.
Our aims were, first, to determine the hypervariable re-
gion which will provide the most comprehensive capture
Table 1 DNA yield when using the modified DNA extraction
protocol
No Bacterial Strain Gram stain Yield
ng/μl
1 Pseudomonas aeruginosa–PA01 Negative 17
2 Bacillus subtilus–NCTC 831 Positive 34.1
3 Escherichia coli–NCTC 8809 Negative >60
4 Listeria monocytogenes–NCTC 2166 Positive 28.7
5 Mycobacterium phlei–NCTC 8151 >60
6 Staphylococcus aureus–NCTC 7447 Positive 36.2
7 Enterococcus faecalis NCTC 370 Positive 40.4
8 Staphylococcus epidermidis Rp62a Positive 8.68
9 Bordetella bronchiseptica–253 Positive >60
10 Peptoclostridium difficile–630 Positive 8
11 Staphylococcus saprophyticus–NCTC 7687 Positive 23.1
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of the microbial diversity in human skin communities;
second, to confirm that the primer set for amplification
of that hypervariable region is specific and will not amp-
lify human DNA contaminants and finally, to compare
the performance of the MiSeq with the Roche 454 plat-
form, which has been the established technology. A low
biomass mock bacterial community was used to test,
optimise and develop the protocol. Skin swabs from
healthy volunteers were also tested to confirm the
method is applicable to the study of the human skin
microbiome.
Results
Bacterial DNA extraction using the MoBio PowerSoil DNA
isolation kit
We modified the MoBio PowerSoil® DNA Isolation kit
manufacturer’s protocol to include and extend the bead
beating and heat incubation steps (see Methods) to
increase the efficacy of lysis of Gram positive bacterial
cell walls. A mock bacterial community (Table 1) was
prepared consisting predominantly of Gram positive
bacteria, including strains representative of known bac-
terial skin microbiota. Bacterial DNA was extracted
using the modified DNA extraction protocol. Adequate
quantities of DNA were obtained (>5 ng/μl), even for
traditionally difficult species (e.g. Staphylococcus species
including Staphylococcus epidermidis RP62A), thus
validating use of the extraction method.
Selection and optimisation of the primer pairs
Initially, three primer pairs (V1-V3: 63 F/519R [18]; V3-V4:
347 F/803R [19] and V4-V5: 517 F/926R [19]) were selected,
all with comparable amplicon length (400 bp-500 bp).
a b
Fig. 1 a Workflow for the validation work on the MiSeq and the Roche 454 NGS platform using positive control: mock bacterial community.
b Workflow for the validation work on the MiSeq and the Roche 454 NGS platform using skin swabs: healthy volunteer samples
Castelino et al. BMC Microbiology  (2017) 17:23 Page 3 of 12
Two aliquots (100 μl) of low concentration (1.42 ng/μl)
mock bacterial DNA community were prepared. One of
the aliquots was spiked with human DNA (2 ng/μl
concentration) (2:1 bacteria: human DNA by volume) to
determine the effect of simulated human DNA contamin-
ation on sequencing reads. During PCR optimisation and
validation the V4-V5 primer pair amplified human DNA
and the primers were, therefore, eliminated from the sub-
sequent workflow. For the remaining primer pairs [V1-V3
(63 F and 519R) and V3-V4 (347 F and 803R)], a single
band was visualised after PCR amplification of the human
DNA spiked and pure bacterial mock DNA communities.
These were then taken forward for re-sequencing, along
with human volunteer (HV) skin swab samples, as shown
in the workflow (Fig. 1).
Comparison of the data obtained from Roche 454 and
MiSeq platforms
Samples and quality control
For the cross-validation of the platforms, skin swabs
from two healthy volunteers were used. Two skin swabs
(one from the right and another from the left cubital
fossa) were obtained from each healthy volunteer. Bac-
terial DNA extracted from each skin swab was amplified
for the V1-V3 and the V3-V4 regions resulting in the
generation of 4 amplicon libraries from each healthy
volunteer. In addition, the mock bacterial community
was divided into two aliquots of which one had simu-
lated human DNA contamination and the other con-
sisted of only the bacterial DNA. These were also
amplified for the V1-V3 and the V3-V4 regions of the
16S rRNA gene to generate four amplicon libraries.
Twelve samples (4 mock communities and 8 amplicon
libraries generated from the four healthy volunteer skin
swabs from two individuals) were sequenced by both the
Roche 454 Junior and MiSeq platforms.
A total of 5.6 Gb data was generated during the
MiSeq run with 85% of the data passing Q30. From the
Roche 454 Junior run >650 Mb data was generated with
53% of the data passing Q25. After quality control,
denoising, merging of paired end reads for the MiSeq
and chimera removal, the MiSeq yielded 5,755,162
reads, at an average length of 264.5 bp (paired reads),
whilst the Roche 454 Junior produced 13,305 reads, at
an average length of 374.2 bp. The phylogenetic ana-
lysis of the data was performed using QIIME [20] soft-
ware and operational taxonomic units (OTU) were
assigned at 97% identity at genus level using the Green-
genes database [21]. Three of the eight HV skin swab
samples passed stringent QC thresholds on both the
MiSeq and Roche 454 Junior, and were available for
subsequent NGS platform comparison.
a b
Fig. 2 a Comparison of the alpha diversity estimates between NGS platforms for the mock bacterial communities. Box and whisker plot (median,
interquartile range and min/maximum values) of the comparison of the Shannon Diversity index (y-axis) values obtained for the mock bacterial
community at genus level classification for the two NGS platforms (x-axis) (n = 4) using Wilcoxon-rank sum test showed no significant difference
between the two platforms (w = 10, p = 0.69). b Comparison of the alpha diversity estimates at genus level distribution for the primers and the
NGS platforms for the mock bacterial community (MiSeq – blue column and Roche454 –red column –values indicated are Shannon diversity
index in each category where n = 1). Mixed V3-4 and Mixed V1-3: Shannon diversity index for the two NGS platforms for the mock bacterial
community with simulated human DNA contamination amplified using primer pair spanning V3-V4 and V1-V3 hypervariable regions of the 16S
rRNA gene. Pure V3-4 and Pure V1-3: Shannon diversity index for the two NGS platforms for the mock bacterial community amplified using primer
pair spanning V3-V4 and V1-V3 hypervariable regions of the 16S rRNA gene
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Comparison of diversity estimates - species richness and
evenness [Shannon-wiener (SW) diversity index]
The diversity at the phylum level was similar for both plat-
forms. The mock bacterial community had an SW diver-
sity index (n = 4 for each platform) of 1.85 and 2 for the
Roche 454 Junior and the Illumina MiSeq platforms, re-
spectively, when calculated based on the genus level distri-
bution (Fig. 2a.). There was no significant difference
observed between the two platforms (w = 10, p = 0.69)
using the Wilcoxon-rank sum test, indicating that the
MiSeq is comparable to the Roche 454 with respect to
identifying the species richness and evenness in the bac-
terial mock community, at the genus level. The SW diver-
sity index compared between platforms for the skin
samples was also found to be similar with no significant
difference observed (w = 14, p = 0.11). The primer pairs
did, however, show within platform differences (Fig. 2b.
SW index for the mock community samples on both
platforms) for the Shannon diversity index values deter-
mined for the mock community samples (n = 1 for each
category). The V3-4 primer pair captured more sequence
diversity than the V1-3 primer pair on the MiSeq (w = 0,
p = 0.03). The Roche 454 data indicated no such observed
difference (w = 9, p = 0.89).
Comparison of abundance of bacterial taxa between
primer pairs and platforms
Data from bacterial mock community
At the phylum level, the mock bacterial communities
showed similar ranking in abundance (Table 2) between
the two platforms, with the three phyla in order of rank
being Firmicutes, Proteobacteria and Actinobacteria. At
this taxonomic level both the primer pairs performed
similarly when assessed on the Roche 454 Junior plat-
form, whereas the amplicons covering the V3-V4 hyper-
variable region on the MiSeq had closer concordance with
the expected distribution of members of the mock com-
munity. Simulated contamination of the mock bacterial
community with human DNA did not affect the taxo-
nomic representation at any level on either platform.
Identification of bacterial taxa was most accurate at
the family level for 9 of the 11 bacteria used in the mock
community, on both NGS platforms (Fig. 3). No effect
of the simulated human DNA contamination was ob-
served, as replicates (with or without the simulated
human DNA contamination) had very good concordance
for the primer pairs when compared within each plat-
form. When the primer pairs were compared between
platforms, the V3-V4 primer pair performed better with
values closer to the expected relative abundance of the
mock community in comparison to that of the V1-V3
primer pair (Additional file 1: Table S1).
The V3-V4 primer pair demonstrated a maximum ab-
solute difference of 7.96% and a minimum of 0.06%
when compared between platforms. The V1-V3 primer
pair however had a larger discrepancy with a maximum
absolute difference of 41.7% and a minimum of 0.29%
when comparing the relative abundances on the two
platforms.
Skin swabs from healthy volunteers
Following quality control, data from three of the HV
skin samples were compared between the two platforms
for the primer pairs. Two of the skin samples were from
the same individual for the V1-V3 and the V3-V4 hyper-
variable region. At the phylum level (Additional file 1:
Table S2a) there was an identical distribution between
the two platforms for the V3-V4 hypervariable region
but less consistency for the V1-V3 hypervariable region.
At the genus level (Additional file 1: Table S2b), again
the V3-V4 primer data showed better concordance
between platforms than the V1-V3 primer pair.
Comparison of beta diversity estimates of the mock
bacterial community and the pilot data from skin swabs
using procrustes PCoA plots
The results of the Procrustes principle coordinates
matrices are presented (Fig. 4a and Fig. 4b) with beta di-
versity estimates using the Unweighted Unifrac and the
Bray Curtis distance matrices for visual representation of
the diversity estimates. The mock bacterial communities
with and without human DNA spiked into the samples
and the three skin samples from healthy volunteers were
available for analysis. The beta diversity for the mock
Table 2 Abundance (%) of bacterial mock community at the level of phylum
Taxonomic
level Phylum
Expected
abundance (%)
MiSeq platform Roche 454 GS Junior
V1-V3 primer pair V3-V4 primer pair V1-V3 primer pair V3-V4 primer pair
MBx MHx MBx MHx MBx MHx MBx MHx
Firmicutes 64 94.03 94.02 68.12 69.81 61.44 53.42 75.43 77.70
Proteobacteria 27 5.60 5.79 25.20 23.65 28.46 33.63 18.43 15.12
Actinobacteria 9 0.26 0.18 6.63 6.52 7.18 11.15 5.03 6.39
MBx In-house mock bacterial community with only bacterial DNA, MHx In-house mock bacterial community with human genomic DNA, V1-V3 primer pair primer
pair targeting the V1-V3 hypervariable region of the 16S rRNA gene, V3-V4 primer pair primer pair targeting the V3-V4 hypervariable region of the 16S rRNA gene,
Roche 454 GS Junior platform pyrosequencing next generation sequencing platform, MiSeq platform sequencing by synthesis next generation sequencing platform
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a b
Fig. 3 Pictorial representation of expected versus the actual relative abundance observed for the individual components of the mock bacterial
community on the MiSeq and Roche454 GS Junior platform for primer pair targeting the (a) V1-V3 hypervariable region and (b) V3-V4 hypervariable
region. Note: In the case of Pseudomonadaceae the MiSeq was able to identify the bacterial component at very low abundance <1.1% relative
abundance for both primer pairs but this was not detected in the Roche454 data. (For the observed relative abundances see Additional file 1: Table S1)
a b
Fig. 4 a Comparison of beta diversity results for the mock bacterial community and the healthy volunteer skin samples sequenced on both Roche
454 and Illumina MiSeq using Procrustes plot comparing the principal co-ordinates of Bray-Curtis distances. b Comparison of beta diversity results for
the mock bacterial community and the healthy volunteer skin samples sequenced on both Roche 454 and Illumina MiSeq using Procrustes plot
comparing the principal co-ordinates of Unweighted UniFrac distances. Lines connect paired sample sequences on the Roche454 (white tip of line)
and Illumina Miseq (red tip of line)
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bacterial community is identical for the V3-V4 primer
pair when compared between the two platforms using
the Unweighted UniFrac distance metric; however the
V1-V3 primer pair shows more variability. By contrast,
when using the Bray Curtis distance matrix which is
based on abundance data for the beta diversity estimates,
minimal variability is observed between platforms and be-
tween primer pairs. Similarly the beta diversity estimates
for the human skin samples showed greater variability
when evaluated using the Unweighted UniFrac for the two
primer pairs on the two platforms when compared to the
results from the Bray Curtis distance matrix.
Discussion
In this paper we have described the development of a
methodology for investigation of a very low biomass
bacterial community using the MiSeq platform and
compared data to that generated using the Roche 454
Junior system.
Comprehensive identification of any bacterial commu-
nity is dependent on several steps including a robust
bacterial DNA extraction method. A major concern with
current protocols is their efficiency for extracting DNA
from Gram positive bacteria, which have cell walls more
resilient to lysis when compared to Gram negative bac-
teria [22, 23]. Given that Gram positive bacteria are
commonly found on skin [24], namely Staphylococcus, a
strength of the current study is that the bacterial DNA
extraction method was first modified to ensure robust
and reproducible capture of these species.
Previous studies [12, 13, 25] have compared the
MiSeq and the 454 platforms but have used either
mock bacterial communities [12, 13] or a single clin-
ical sample [25]; by contrast, we have used both a
mock community to show the accuracy of the V3-4
primer pair on the MiSeq platform when compared
to the Roche454 and human samples to demonstrate
that the primer pair will amplify sufficiently even in
the low biomass environment of the skin.
The Microbiome Quality Control Project [26] recom-
mends the use of a mock community containing taxa
typical of site-specific microbial communities as a posi-
tive control in studies. Our work used the framework for
human microbiome research [3] and included such a
mock bacterial community to provide evidence for
consistency and accuracy of the protocol. The mock
community included a known skin commensal, Staphy-
loccocus species, which have been implicated in skin dis-
eases such as atopic eczema where there is an increase
in their abundance [27] and in psoriasis where reduced
abundance has been reported [28]. In addition, the effect
of simulated human DNA contamination was assessed.
There have been studies on the effect of laboratory and
reagent contamination in low biomass samples [10], on
human-derived RNA-seq datasets [29] and bacterial con-
tamination in human genome sequencing [30]. However,
there is no information on the effect of human DNA
contamination on the resulting output which is espe-
cially relevant in microbiome work on the skin as the
bacterial biomass is low in comparison to the host gen-
etic DNA that may contaminate the skin swab samples.
Our work shows that the presence of human DNA does
not affect the final output when compared to the results
of the sequencing of the DNA from pure bacterial iso-
lates increasing the confidence in the results obtained in
human-derived samples. The data in the NIH Human
Microbiome project [5] was derived from pyrosequenc-
ing using the Roche 454 FLX Titanium technology using
amplicons generated from V1-V3 and V3-V5 hypervari-
able regions. The longer read lengths of 454 technologies
cover a larger region of the 16S gene than the MiSeq
and, therefore, enable easier taxonomic assignment.
Shorter read lengths are sufficient to analyse microbial
communities [11, 31], but limits the ability to maximize
the capture of taxonomic diversity; therefore, we used
the full capacity of the MiSeq with the 2x 250 bp paired
end run (available at the time of the work) to achieve
the optimal capture of data. Results demonstrated that
the MiSeq performance was similar to the Roche 454
Junior platform in identifying community diversity for
both the mock bacterial community and the skin sam-
ples at the phylum and the genus level.
Studies using the MiSeq platform have commonly
used the V4 primer pair [11, 32] or the V3 primer pair
[33], which limits the read length to ~250 bp. Our study
demonstrates that the longer amplicons across the V3-
V4 hypervariable region were identical for the abun-
dance of the bacterial community identified and the beta
diversity estimates when analysed on the MiSeq or
Roche 454 Junior platforms. However, the MiSeq is
more cost effective, as evidenced by the much higher
coverage (>400x) obtained when compared to the Roche
454 Junior, using similar library preparation steps.
This work contributes to the evidence [12, 13, 34, 35]
that the MiSeq is a suitable sequencing platform for pro-
filing bacterial communities using analysis of 16S rRNA
gene fragments. However, some limitations are apparent.
We did not sequence negative controls which are con-
sidered as a measure of determining erroneous results
[10] due to contamination as there was no detectable
product in the samples. In our mock community we ob-
served less than 5.5% in total abundance of other bacter-
ial species and Rhizobium and Paracoccus, which have
been reported as contaminating species in negative con-
trols previously [10], showed abundances of less than
0.1%, lower than the traditional threshold (>1%) of abun-
dance for inclusion in analysis. Another limitation of the
current study reflects the rapidly evolving nature of
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microbiome research and the availability of advanced
NGS with longer reads such as single molecule real time
(SMRT) sequencing technologies which have not been
explored or cross-validated. However, the results of this
study show that the data generated by the MiSeq bench-
top sequencer, which is now replacing the Roche454
platform in academic departments, is comparable.
Therefore the data generated using the V3-V4 primer
pair using the MiSeq can be compared with the existing
data in the human microbiome literature.
Four of the eight skin samples showed high levels of
chimera (~20%) on data analysis on the MiSeq platform
and could not be confidently included in the compara-
tive analysis between platforms. This is likely due to
PCR artefacts introduced as a result of incomplete ex-
tension of the DNA template, or may be linked to the
low starting biomass available, as well as the limitation
of the sequence read length of the MiSeq. PCR based limi-
tations are inherent in these analyses due to the need for
amplification from low biomass samples and need to be
taken into account when preparing libraries. Strategies to
suppress the artificial chimera formation during PCR
amplification have been reported [36–39] and could be
used to minimize chimera generation during PCR. The
loss of samples, though not anticipated at the outset of the
work, has also been observed in a larger study investigat-
ing the skin microbiota in psoriasis [28]. Even in that
study, the data from one of the primer pairs which
targeted the V3-V5 hypervariable region could not be ana-
lysed as ~60% of the samples had to be removed due to
amplification and sequencing depth quality issues even be-
fore the data analysis could be conducted. In the current
work only one paired sample was lost due to sequencing
depth issues and there were no losses due to PCR amplifi-
cation. However, at the data analysis stage, four of the
remaining skin swabs had high levels of chimeras detected
and were therefore discarded from further analysis. This
highlights the limitations that researchers should antici-
pate and try to mitigate against when studying low bacter-
ial biomass samples. The mock community data could
only be assigned to the family level in the taxonomic
identification. This was considered to be the result of a
combination of factors including the drop in quality of the
MiSeq reads beyond 200 bps which resulted in a com-
promise in the quality of the 50 bp overlap, necessary for
joining the paired end reads and the subsequent read/se-
quence assignment. It is expected that the upgraded
version of the MiSeq chemistry, supporting the 300 bp
paired end runs, will reduce the bias introduced due to in-
adequate read overlap at the sequencing stage and allow
better taxonomic assignment. However, it was observed
that in the HV skin samples, this was not a limiting factor
as bacteria could be identified to the genus level despite
using the version 2 chemistry on the MiSeq.
Conclusions
Our study reports on the optimization of a protocol
that can be used in investigating a low microbial bio-
mass community, such as in skin samples. We have
shown that the method is robust to spiking of human
DNA into a low bacterial skin biomass mock commu-
nity sample. Furthermore, we have demonstrated that
the community diversity can be captured using the V3-
V4 hypervariable region of the bacterial 16S rRNA gene
for NGS and that the MiSeq is a suitable next gener-
ation sequencing platform, providing comparable data
to the Roche 454 GS Junior, with similar capture of
bacterial diversity, but with a much improved through-
put and cost effectiveness. Therefore, our results pro-
vide evidence for validation of the MiSeq platform
against the Roche454 using a known mock bacterial
community containing typical skin bacteria and also
evidence that the optimised method can be used in
human clinical samples.
Methods
Aim, design and setting of study
The aim of the study was to optimise and validate the
method for generation of the 16S rRNA library and
compare the MiSeq against the 454 platform for the 16S
rRNA data generated when using low bacterial biomass
samples such as skin swabs to study the human bacterial
microbiome.
Subjects
Healthy volunteers (age range 30–50 years) were recruited
to this study after obtaining informed verbal consent
(MREC 99/8/84). They had no history of skin diseases or
evidence of skin infections and had not used topical anti-
biotics, topical steroids or systemic antibiotics in the last
6 months. Healthy volunteers (n = 2: for initial validation
of the MoBio Power Soil® DNA Isolation kit; n = 6: for
optimization of PCR; n = 4: for initial ligation of adapters
and index primers; n = 2: for resequencing of 16S rRNA
amplicons on the MiSeq and the Roche 454 GS Junior
platform) were identified and screened for any exclusion
criteria (Additional file 1: Skin sampling) using a modifica-
tion of the NIH HMP sampling protocol. The right and
left antecubital fossae were sampled from each healthy
volunteer labelled and processed separately.
Sample collection
After obtaining consent, each individual was given writ-
ten instructions about skin preparation prior to sampling
and soap (without any anti-bacterial ingredient) was
provided for hygiene needs for the two weeks before
sampling. The sampling technique described in the NIH
Microbiome manual of procedures [40] was used to col-
lect the samples in an aseptic manner using Catch-All™
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(Epicentre®) swabs pre-moistened with sample collection
fluid (50mMol Tris with 1 mM EDTA and 0.5% Tween
20). To increase the yield of the skin bacterial flora the
NIH protocol was modified to ensure that 4 cm2 area of
skin at the antecubital fossa was swabbed. The swabs
were inserted into, and transported in MoBio Power
Bead® collection tubes and processed within 3 h of
sampling. The work flow for the sample processing is
illustrated in figure (Fig. 1).
Method development
Selection of bacterial DNA extraction kit
The MoBio Power Soil® DNA Isolation kit was selected
for use in this project as the kit is used as standard in
the protocols followed by the NIH Human Microbiome
Project [40].
Bacterial DNA extraction
Bacterial DNA extraction was carried out using the
MoBio PowerSoil® DNA Isolation Kit protocol with the
following modification. To increase the efficiency of the
microbial cell lysis the duration of mechanical and chem-
ical lysis was increased with introduction of a 15 min in-
cubation period at 70 °C in the cell lysis process after the
addition of MoBio buffer C1 solution. A final volume of
50 μl of elution buffer was used for recovery of bacterial
DNA from columns following extraction.
The extracted DNA was quantified using the Qubit®
dsDNA HS Assay fluorometric quantitation kit as per
manufacturer’s instructions (Invitrogen, Life Sciences).
Eleven different bacterial isolates (from an in house
collection) were inoculated onto standard growth media
and incubated in an appropriate atmosphere at 37 °C for
18 h. DNA was extracted using the above method and
was diluted with PCR grade water to the mean DNA
concentration of the samples (~1 ng/μl). The mock com-
munity was prepared by combining equal volumes
(10 μl) of the individual bacterial isolates. The concen-
tration of the mock bacterial community was 1.42 ng/μl
which was similar to the concentration of the DNA ex-
tracted from skin samples (1.2 ng/μl). This was done to
ensure that the concentration of DNA template ampli-
fied in the downstream PCR reactions were uniform in
all reactions.
PCR and primers
Selection of primers
The consensus in the published literature favoured the
inclusion of the V1-V4 hypervariable regions for bacter-
ial identification as it captures the diversity of the bacter-
ial microbiome when used on the 454 pyrosequencing
platform. PCR primers were selected after optimisation
of different PCR primer sets. Initial primer pairs (V1-V3:
63 F CAGGCCTAACACATGCAAGTC and 519R GTA
TTACCGCGGCAGCTGGCAC [18]; V3-V4 347 F GGA
GGCAGCAGTRRGGAAT and 803R CTACCRGGGTA
TCTAATCC [19] and V4-V5: 517 F GCCAGCAGCC
GCGGTAA and 926R CCGTCAATTYYTTTRAGTTT
[19]) were selected based on the amplicon length (dic-
tated by the capacity of the MiSeq 2x 250 paired end
run to generate sequencing reads with a minimum over-
lap of 20 bp between the forward and the reverse read
and for uniformity of product size ~450 bp) and product
position (primers targeting the hypervariable regions
across V1-V5 of the 16S rRNA gene that were used in
the Human Microbiome Project [41] to generate data
that could be compared against the Human Microbiome
Database).
Polymerase Chain Reaction for initial amplification of
bacterial DNA
A 50 μl PCR reaction using NEBNext® High-Fidelity 2X
PCR Master mix (New England Biolabs®) using the 5 ng-
1 μg total DNA template reaction master mix protocol
[25 μl of NEBNext® High-Fidelity 2X PCR Master Mix
(New England Biolabs®), primer pair mix 20 μl (25 μM
concentration) and 23 μl of extracted DNA] was assem-
bled. The work was performed under a UV hood in
DNA free cabinet and the PCR mix was immediately
transferred to a thermocycler (M J Thermocycler) pre-
heated to 98 °C. The PCR cycling conditions were 98 °C
for 30 s, followed by 35 cycles of 98 °C for 10 s, anneal-
ing temperature of 60 °C for V1-V3 primer pair or 56 °C
for V3-V4 primer pair for 30 s and 72 °C for 30 s, and
72 °C for 10 mins. These thermocycling conditions were
based on the optimization work on the PCR.
Bacterial DNA library preparation for MiSeq re-
sequencing of 16S amplicons
The PCR products were purified using the Agencourt®
AMPure® XP and quantified using the Qubit® Fluro-
metric Quantitation (Life Sciences, Invitrogen) dsDNA
HS Assay and found in the range of 1445 ng to 1925 ng
of DNA products.
The NEBNext® Ultra® DNA Library Prep Kit for
Illumina was used to prepare the DNA library as this kit
has been optimised for low concentration (5 ng-1 μg)
DNA input. This was ideal as the samples had total
DNA input between 25-50 ng.
The resultant libraries were divided at this stage for
the ligation of the specific adapters for the Illumina and
the Roche 454 GS Junior platforms. The 454 pyrose-
quencing was carried out after cleanup following stand-
ard procedures at this step as the library was also
barcoded here.
For the Illumina platform, the NEBNext® Ultra® DNA
Library Prep Kit was used to barcode the adapter-ligated
DNA as per protocol for 50 ng input DNA to enable
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multiplexing of the extracted bacterial DNA library. The
16S amplicon libraries were quantified using qPCR, nor-
malized and pooled after determining the size of the
amplicons using the Agilent Bioanalyser. 5 μl of the
pooled 4nM DNA library was prepared for sequencing
as per the MiSeq benchtop sequencer manufacturer’s
protocol. As the DNA library was expected to have low
diversity, the pooled samples were combined with
denatured and diluted PhiX control (50% of the total
volume). This resultant library was sequenced on the
MiSeq Benchtop Sequencer to produce 2 x 250 paired
end reads.
Method validation
MoBio PowerSoil® DNA Isolation Kit Validation
Initial validation of the bacterial DNA extraction technique
using the MoBio PowerSoil® DNA Isolation Kit was carried
out using Staphylococcus epidermidis strain RP62A. This
is a recalcitrant Gram positive bacterium, which is consid-
ered to be the most prevalent staphylococcal species in
humans [42]. Two replicates of the extraction and blank
extraction controls were simultaneously processed. A
single band was identified in the extracted replicates on
agarose gel electrophoresis. The DNA extraction protocol
was modified during this process and this was validated by
extracting bacterial DNA from eleven different strains of
bacteria as described above.
Quality control
To detect contamination
Simultaneously with each bacterial DNA extraction, a
blank extraction kit control was conducted to ensure de-
tection of any contaminants from the extraction kits.
With each PCR reaction a negative control with no
DNA template (volume substituted with PCR grade
water) was also processed simultaneously for each
primer pair to detect contamination from any source
including PCR reagents. These control samples were
processed through to the ligation of adapters and index
primers. At each stage after amplification the products
were quantified using Qubit® and visualized through
agarose gel electrophoresis. No bands were visible on gel
electrophoresis prior to the ligation of adapters and
index primers and after the indexing of the library in the
blank extraction kit control and negative (no DNA tem-
plate) control for the PCR reactions.
To detect contamination from human DNA
During the optimization process to detect if contamin-
ation of the samples by host (human) DNA would pro-
duce erroneous results, varying proportions of extracted
human DNA were added to the mixed positive controls
and PCR amplification was undertaken using the
selected primer sets. There was no amplification ob-
served in the samples that were composed entirely of
human DNA, demonstrating the specificity of the
primers for bacterial targets.
To ensure validity of the kits and PCR reagents
A positive control (consisting of only one species of
bacteria) was processed at every bacterial DNA extrac-
tion when working with skin samples, to ensure that the
extraction kits and reagents were functional. In order to
ensure that the protocol worked for every batch of the
skin samples that were processed the positive control
was also processed. At each stage after amplification the
products were quantified using Qubit®, diluted to the
same quantity as the samples and visualized using gel
electrophoresis. Single bands were visualized at each gel
electrophoresis that confirmed the presence of the
appropriate PCR end product.
Statistical data analysis
The microbial data was described using quantitative mea-
sures of community composition that take into account
the presence and the abundance of a given taxa using the
Shannon-Wiener alpha diversity index. To compare the
alpha diversity estimates between the two NGS platforms
and the primer pairs the non-parametric Wilcoxon rank
sum test was used. For a visual comparison of the beta
diversity estimates Procrustes analysis was carried out
using the QIIME pipeline. The unweighted UniFrac and
the Bray-curtis distance matrices were applied to the ana-
lysis to assess the beta diversity estimation on the two
platforms for the qualitative (presence/absence of OTUs)
and quantitative (abundance estimates) measures respect-
ively when using the two different primer pairs on the two
different sequencing platforms.
Additional file
Additional file 1: Table S1. Comparison of the relative abundance (%)
of bacterial mock community at the classification level of family. Table
S2a. Comparison of the relative abundance (%) of bacterial taxa from
healthy human skin samples at the phylum level (data available for two
samples for the V3-V4 primer pair and one sample for V1-V3 primer pair).
Table S2b. Comparison of the relative abundance (%) of bacterial taxa
from healthy human skin samples at the genus level (data available for
two samples for the V3-V4 primer pair and one sample for V1-V3 primer
pair). Skin sampling: Requirements for skin sampling and skin
preparation instructions provided to healthy volunteers. (DOCX 40 kb)
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16S rRNA gene: 16S ribosomal ribonucleic acid – A component of the 30S
small subunit of prokaryotic ribosomes; bp: Base pair; DNA: Deoxyribonucleic
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collection of type cultures; Q: Quality score eg: Q30 is Phred Score 30, 99.9%
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